The American College of Cardiology's (ACC) ACCEL Lite podcast highlighted a significant advancement in preventive cardiology: AI-enabled nationwide opportunistic screening of non-contrast chest CT scans for predicting death and cardiovascular (CV) outcomes. This innovative AI technology moves beyond simple detection to precisely quantify key cardiovascular imaging risk factors, such as heart calcification, aorta calcification, and fat around the heart, from routine chest CT scans initially performed for other reasons. This method allows clinicians to more accurately identify high-risk patients and intervene earlier to help prevent serious cardiac events like heart attacks and strokes. The potential for such widespread screening is underscored by studies, including a nationwide cohort study in Taiwan utilizing the National Health Insurance Research Database, which found a clear association between AI-enabled cardiac calcium scoring from non-contrast chest CTs and all-cause mortality/cardiovascular events. Further corroborating the viability and growing acceptance of this technology, the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to HeartLung Corporation for its AI-CVD software. This platform offers a variety of automated assessments for preventive multisystem screening based on a single CT scan, integrating 10 FDA-cleared modules for quantitative cardiovascular evaluations. Another HeartLung Technologies product, AutoChamber, also received FDA clearance for assessing chest CT scans for signs of coronary artery disease (CAD) and other potentially fatal heart conditions, further validating the technology's regulatory progress. The consistent findings from research and regulatory approvals demonstrate the robust and transformative potential of AI in enhancing cardiovascular disease detection and prevention strategies globally.